HANSOH Financial Statements From 2010 to 2024
| 3KY Stock | EUR 2.16 0.06 2.70% |
Check HANSOH PHARMAC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HANSOH PHARMAC's main balance sheet or income statement drivers, such as , as well as many indicators such as . HANSOH financial statements analysis is a perfect complement when working with HANSOH PHARMAC Valuation or Volatility modules.
HANSOH |
HANSOH PHARMAC HD 00001 Company Shares Outstanding Analysis
HANSOH PHARMAC's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current HANSOH PHARMAC Shares Outstanding | 5.92 B |
Most of HANSOH PHARMAC's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HANSOH PHARMAC HD 00001 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, HANSOH PHARMAC HD 00001 has 5.92 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all Germany stocks is significantly lower than that of the firm.
HANSOH PHARMAC HD Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HANSOH PHARMAC's current stock value. Our valuation model uses many indicators to compare HANSOH PHARMAC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HANSOH PHARMAC competition to find correlations between indicators driving HANSOH PHARMAC's intrinsic value. More Info.HANSOH PHARMAC HD 00001 is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for HANSOH PHARMAC HD 00001 is roughly 2.17 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HANSOH PHARMAC's earnings, one of the primary drivers of an investment's value.About HANSOH PHARMAC Financial Statements
HANSOH PHARMAC stakeholders use historical fundamental indicators, such as HANSOH PHARMAC's revenue or net income, to determine how well the company is positioned to perform in the future. Although HANSOH PHARMAC investors may analyze each financial statement separately, they are all interrelated. For example, changes in HANSOH PHARMAC's assets and liabilities are reflected in the revenues and expenses on HANSOH PHARMAC's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in HANSOH PHARMAC HD 00001. Please read more on our technical analysis and fundamental analysis pages.
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the Peoples Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd. HANSOH PHARMAC operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11645 people.
Currently Active Assets on Macroaxis
Other Information on Investing in HANSOH Stock
HANSOH PHARMAC financial ratios help investors to determine whether HANSOH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HANSOH with respect to the benefits of owning HANSOH PHARMAC security.